OCTREOTIDE PROOF OF CONCEPT IN IIH PATIENTS
Six open label studies with injectable octreotide have shown the drug to be effective in lowering intracranial pressure [ICP], reducing headache, and improving visual symptoms when administered up to 3 times a day. Intranasal delivery aims to reduce the frequency of administration, enable the use of lower amounts of drug, lower systemic side effects, and avoid pain and discomfort associated with an injectable product.